Fairmount Funds Management
VC Fund
Philadelphia, United States
Fairmount Funds Management is a Philadelphia-based investment firm.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Fairmount Funds Management invests in
Stages Fairmount Funds Management invests in
Countries Fairmount Funds Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Peter Harwin
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 16 (43%)
- Health Care 14 (38%)
- Therapeutics 11 (30%)
- Biopharma 7 (19%)
- Pharmaceutical 6 (16%)
Stage
- Post-IPO Equity 14 (38%)
- Series A 4 (11%)
- Series B 3 (8%)
- Funding Round 2 (5%)
- Seed 1 (3%)
Country
- United States 15 (41%)
- France 1 (3%)
- Denmark 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Peter Harwin
Co-Founder and Managing Member
|
Co-Founder and Managing Member | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mentari Therapeutics
|
Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M / Private Equity / Jul 22, 2026 | |
Crescent Biopharma
|
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $185M / Post-IPO Equity / Dec 04, 2025 | |
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M / Post-IPO Equity / Nov 10, 2025 | |
|
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M / Post-IPO Equity / Nov 10, 2025 | |
|
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M / Post-IPO Equity / Nov 10, 2025 | |
Jade Biosciences
|
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $135M / Post-IPO Equity / Oct 07, 2025 | |
Oruka Therapeutics
|
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases. | $180M / Post-IPO Equity / Sep 17, 2025 | |
|
Crescent Biopharma
|
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $200M / Post-IPO Equity / Jun 16, 2025 | |
|
Jade Biosciences
|
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $300M / Post-IPO Equity / Apr 29, 2025 | |
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M / Jan 01, 2025 | |
| See all 37 investments → | |||
Co-Investors
Venrock Healthcare Capital Partners
26 deals together
Perceptive Advisors
17 deals together
Commodore Capital
12 deals together
RA Capital Management
11 deals together
Wellington Management
11 deals together
RTW Investments
10 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Fairmount Funds Management invest in?
Fairmount Funds Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series A stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fairmount Funds Management?
Public channels for Fairmount Funds Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fairmount Funds Management?
The team at Fairmount Funds Management includes Peter Harwin (Co-Founder and Managing Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
